CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar

Moolky Nagabhushan, Casey M. Miller, Theresa P. Pretlow, Joseph M. Giaconia, Nancy L. Edgehouse, Stuart Schwartz, Hsing-Jien Kung, Ralph W deVere White, Paul H. Gumerlock, Martin I. Resnick, Saeid B. Amini, Thomas G. Pretlow

Research output: Contribution to journalArticlepeer-review

217 Scopus citations

Abstract

Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.

Original languageEnglish (US)
Pages (from-to)3042-3046
Number of pages5
JournalCancer Research
Volume56
Issue number13
StatePublished - Jul 1 1996

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar'. Together they form a unique fingerprint.

Cite this